Multiple myeloma (MM) is preceded by the asymptomatic pre-malignant state, monoclonal gammopathy of undetermined significance (MGUS). Although MGUS patients may remain stable for years, they are at increased risk of progressing to MM. A better understanding of the relevant molecular changes underlying the transition from an asymptomatic to symptomatic disease state is urgently needed. Our studies show for the first time that the CD147 molecule (extracellular matrix metalloproteinase inducer) may be having an important biological role in MM. We first demonstrate that CD147 is overexpressed in MM plasma cells (PCs) vs normal and pre-malignant PCs. Next, functional studies revealed that the natural CD147 ligand, cyclophilin B, stimulates MM cell growth. Moreover, when MM patient PCs displaying bimodal CD147 expression were separated into CD147 bright and CD147 dim populations and analyzed for proliferation potential, we discovered that CD147 bright PCs displayed significantly higher levels of cell proliferation than did CD147 dim PCs. Lastly, CD147-silencing significantly attenuated MM cell proliferation. Taken together, these data suggest that the CD147 molecule has a key role in MM cell proliferation and may serve as an attractive target for reducing the proliferative compartment of this disease.
INTRODUCTION
Multiple myeloma (MM) is a malignancy characterized by the clonal expansion of malignant plasma cells (PCs) that reside primarily within the bone marrow (BM) and is defined as having X10% PCs and X3 g/dl of monoclonal immunoglobulin (Ig; M-protein), along with end-organ damage, which may include lytic bone lesions. MM is preceded by the asymptomatic, premalignant disorder monoclonal gammopathy of undetermined significance (MGUS), 1, 2 which is defined as presenting with o10% PCs in the BM, a serum M-protein of o3 g/dl, and no end-organ damage. 3 Although the clonal MGUS PC population may remain remarkably stable for years, MGUS patients have a life-long, significantly increased risk of progressing to overt MM at a rate of 1% per year. 3, 4 Treatment of these patients is not initiated until transformation has occurred and serious endorgan damage emerges. 5 Although there have been significant advances in treatment of this disease, MM patients continue to have a high mortality rate with a median survival rate of only 4-7 years. 6 Although many groups have helped to define phenotypic markers that generally distinguish MM PCs from normal BM PCs (NBMPCs), for example, CD19, 7 no such marker is currently available that permits distinction between MGUS and MM clonal PCs or has the capability to discern those cells with proliferative potential. In the present study, we examine the possibility that the CD147 molecule may be having an important role in MM disease biology. CD147, also known as extracellular matrix metalloproteinase (MMP) inducer, is a ubiquitously expressed transmembrane glycoprotein belonging to the Ig superfamily 8 and its various functions have been the topic of recent reviews. 8, 9 Although CD147 is expressed widely on many cell types, albeit often at very low levels, there is extensive literature describing its aberrantly elevated expression in human cancer. [10] [11] [12] Moreover, CD147 levels have been shown to increase during progression from benign to malignant disease in a number of solid tumors. [13] [14] [15] Dysregulation of CD147 in tumor cells has been shown to stimulate increased angiogenesis 16 and production of MMPs, resulting in degradation of the extracellular matrix, tumor growth and metastasis. 17 CD147 has also been suggested to protect cancer cells from the apoptosis-like fate, anoikis. 18 Finally, CD147 binds to its natural ligands, cyclophilin A (CypA) and CypB, 19, 20 together with heparin sulfate proteoglycans, thereby promoting cellular proliferation. 21 Cyps are cellular proteins, which were once thought to have roles limited to intracellular functions. However, it is now universally accepted that these proteins can be secreted under inflammatory conditions and have a role as soluble mediators of intercellular communication. 22 Although extracellular CypA and CypB have been reported to support anti-apoptotic action and contribute to STAT3 signaling and survival in MM cells, 23 to our knowledge, the association of CD147 with Cyps in MM has not been previously demonstrated.
Because of the collective evidence in the literature concerning correlation of CD147-expression levels with malignant progression, in this study, we investigated CD147-expression levels across the disease continuum of MGUS to MM and its potential role in malignant PC proliferation.
MATERIALS AND METHODS

Patient material
MGUS and MM patient BM aspirates were collected as part of the routine clinical examination. BM aspirates obtained from patients undergoing spine surgeries without coincident B-lineage malignancies served as a source of NBMPCs. The Mayo Clinic Institutional Review Board approved the protocol to obtain samples from healthy donors, as well as from individuals with monoclonal gammopathies. Written informed consent to participate in this research study was provided by all the subjects from whom BM aspirates were drawn in accordance with the Declaration of Helsinki. Normal donor peripheral blood served as a source of normal B cells. BM aspirate mononuclear cells were isolated by Ficoll-Paque (GE Healthcare, Piscataway, NJ, USA) density gradient centrifugation. Both MM and normal PCs were isolated from the patient BM aspirates by magnetic bead separation using the human CD138 positive selection kit (StemCell Technologies, Vancouver, British Columbia, Canada) and a Robosep Cell Separator (StemCell Technologies).
Peripheral blood B lymphocytes were enriched to 495% purity by negative selection using StemCell Technologies B-cell enrichment cocktail. Peripheral blood B cells were activated by culturing cells at 37 1C in a 5% CO 2 incubator for 5 days in the presence of 10 mg/ml CpG (oligodeoxynucleotide 2006 5 0 -TCGTCGTTTTGTCGTTTTGTCGTT-3 0 ), interleukin (IL)-2 (100 U/ml; Fitzgerald Industries International, Acton, MA, USA) and IL-15 (10 ng/ml; Peprotech, Rocky Hill, NJ, USA).
Cell lines and culture medium
The human myeloma cell lines (HMCLs) ANBL-6, 24 ALMC-2 25 and MCG were all derived in our laboratory. The IL-6-independent RPMI 8226 HMCL was purchased from ATCC (Manassas, VA, USA). All the HMCLs were maintained in Iscove's Modified Dulbecco's media supplemented with 50 U/ml penicillin G, 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) and 5% heat-inactivated fetal calf serum (PAA Laboratories, Etobicoke, Ontario, Canada). Recombinant IL-6 was used at a final concentration of 1 ng/ml (Novartis, Basel, Switzerland). Recombinant IGF-I was used at a final concentration of 10 mg/ml (Sigma-Aldrich, St Louis, MO, USA).
DNA-synthesis assays
DNA-synthesis assays measuring [ 3 H]-thymidine (PerkinElmer, Waltham, MA, USA) incorporation were performed as previously described. 26 Cells were incubated in Iscove's Modified Dulbecco's media plus 0.5% bovine serum albumin (Celliane, Norcross, GA, USA) with or without 1 ng/ml IL-6 and 10 nM CypB (Prospec, Rehovot, Israel) at 37 1C in the presence of 5% CO 2 . For CD147-blocking studies, cells were incubated with or without 0.5 mg/ml of either an isotype-matched control Ab with irrelevant specificity (MOPC-21; Sigma-Aldrich) or an a-CD147-neutralizing antibody (Novus Biologicals, Littleton, CO, USA) for 2 h prior to stimulation with IL-6 or CypB. After the indicated length of incubation, DNA synthesis was measured. Data are presented as either the mean [ 3 H]-thymidine incorporation of triplicate samples or data from independent experiments þ / À s.e.m.
Cell cycle and DNA content analysis
Mononuclear cells were incubated with complete Iscove's Modified Dulbecco's media containing 10 mM bromodeoxyuridine (BrdU) overnight prior to staining the next day using a BrdU-APC flow kit (BD Biosciences, San Diego, CA, USA), as previously described. 27 Cells were stained for CD147 followed by fixing and permeabilization before treating with 30 mg/ml DNAse for 1 h at 37 1C and staining with anti-BrdU. Finally, 7-AAD was added to the sample. For DNA content analysis, cells were cultured for 24 h before washing in cold phosphate-buffered saline prior to the slow addition of 1 ml ice-cold ethanol while vortexing. Cells were incubated overnight at À 20 1C, washed twice in cold phosphate-buffered saline and incubated for 20 min with 50 ml of RNase A (10 mg/ml) at 37 1C. A total of 400ml of 50 mg/ml propidium iodide was added to samples prior to analysis on the FACStar (BD Biosciences). Data were analyzed using FlowJo (Tree Star, Ashland, OR, USA).
RNA isolation, cDNA synthesis and sequence analysis of immunoglobulin heavy chain variable region (IGHV) genes Total cellular RNA was extracted from purified PCs from MGUS and MM patients and healthy donors using the Trizol reagent (Invitrogen). A total of 2 mg RNA was converted to cDNA using the GE Healthcare. First Strand Synthesis kit, and cDNA was amplified by PCR using the Qiagen (Valencia, CA, USA) HotStarTaq MasterMix kit and primers specific for CD147 and bactin as an internal control. The CD147 primers used were: forward 5 
Western blot analysis
Cells were lysed for 45 min on ice in lysis buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 0.5 mM MgCl 2 , 0.5 mM CaCl 2 , 10 mM NaF, 10 mM Na 4 P2O 7 , 1% NP-40, 10% glycerol, 0.1% sodium dodecyl sulphate, 2 mM EDTA, complete mini protease inhibitor cocktail and phosSTOP phosphatase inhibitor cocktail (Roche, Indianapolis, IN, USA). Lysates were cleared of insoluble material by centrifugation and subjected to 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis before transfered to a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA) and blocked with 25 mM Tris-HCl (pH 7.2), 150 mM NaCl and 0.1% Tween 20 (TBST) plus 5.0% Blotto (ISC BioExpress, Kaysville, UT, USA). The blot was probed with anti-CD147 antibody (GeneTex, Irvine, CA, USA) at a 1:2500 dilution, anti-phospho mitogen-activated protein kinase (MAPK) or anti-total MAPK at a 1:1000 dilution (NEB, Ipswich, MA, USA) or anti-b-actin antibody (Novus) at a 1:5000 dilution. Horseradish peroxidase-conjugated secondary antibodies (GE Healthcare) were used at a 1:2000 dilution. SuperSignal (Pierce, Rockford, IL, USA) chemiluminescent substrate was used to detect proteins.
Small interfering RNA (siRNA) transfection parameters CD147/BSG siGenome siRNA duplexes (target sequences are proprietary) were synthesized and purchased from Dharmacon Research, Inc. (Lafayette, CO, USA). Transfection of the siRNA duplexes was achieved via electroporation as previously described. 29 Briefly, cells were transfected with CD147 siRNA and subsequently plated in normal growth media. Twentyfour hours after the first transfection, a second transfection with CD147 siRNA was performed and cells were plated in normal growth media. Twenty-four hours following the second transfection, cells were washed twice prior to culture (2.5 Â 10 4 cells per well in a final volume of 200 ml in 96-well flat bottom microtiter plates and 2.5 Â 10 5 cells per well in a final volume of 2 ml in 24-well flat bottom plates). All the cultures were performed in triplicate in the presence of 0.5% bovine serum albumin and IL-6 (1 ng/ml) for 3 days at 37 1C in the presence of 5% CO 2 . At 48 h following culture commencement in the 96-well microtiter plates, cultures were pulsed with 1 mCi 
Statistical analysis
Statistical analysis was performed using a Wilcoxon rank test. Values of P o0.05 were considered significant. CD147 and its role in myeloma cell proliferation BK Arendt et al
RESULTS
Elevated expression of CD147 in MM PCs
To determine whether there was a biological role for CD147 in MM, we assessed CD147 mRNA expression levels in purified PCs obtained from a series of MGUS and MM patients. We observed notably higher CD147 mRNA levels in MM PCs vs MGUS PCs ( Figure 1a ). Figure 1b illustrates CD147 mRNA levels across a spectrum of normal resting and activated B cells and BM PCs compared with MGUS and MM patient PC samples. In contrast to MM PC CD147 mRNA levels, CD147 mRNA levels were considerably lower in MGUS PCs, NBMPCs and resting and activated normal B cells.
We next examined whether CD147 mRNA expression levels correlated with MGUS and MM PC cell-surface CD147 expression. Flow cytometric analysis revealed several patterns ( Figure 2a , bottom panels): (1) uniform lack of CD147 expression (MGUS patient); (2) uniform CD147 dim expression (MM patient 1); (3) bimodal CD147 expression (MM patient 2); and (4) uniform CD147 bright expression (MM patient 3). This methodology was used to assess CD147 levels on an additional 17 MGUS and 104 MM patients and Figure 2b shows that PCs from MM patients expressed significantly higher levels of CD147 than did PCs from MGUS patients. Finally, we performed western blot analysis to evaluate CD147 protein expression, as this method allowed us to visualize differences in glycosylation patterns. There is evidence that the higher glycosylated form of CD147 is the active form, as it induces MMP production 17, 30, 31 and metastasis. 32, 33 Figure 2c shows that CD147 was undetectable in normal B cells using this method, whereas MGUS PCs displayed extremely low levels of this molecule. In contrast, CD147 protein was clearly evident in the ANBL-6 and ALMC-2 HMCLs and in each of the four patient MM PC samples analyzed. Of interest, both high and low glycosylated forms of CD147 were observed in both HMCLs and MM patient samples, albeit to varying degrees. Collectively, these data demonstrate that MM cells on average express increased levels of CD147 mRNA and protein as compared with MGUS PCs.
Increased CD147 expression may accompany MM disease progression To determine whether CD147-expression levels correlate with MM disease progression, serial CD138 þ MM PC samples from three patients were analyzed. At the time of initial assessment, MM patient 1 was clinically diagnosed with asymptomatic but progressive disease and markedly elevated BM PCs (60%) and IgA levels (1610 mg/dl). Figure 3a demonstrates that CD147 was clearly detectable on the MM PCs at this stage. Upon reassessment 9 months later, the level of BM PCs had risen to 70% and CD147 levels increased by over six-fold (Figure 3b ). After 1 month, MM patient 1 succumbed to disease. MM patient 2 was initially assessed after having received an autologous peripheral blood stem cell transplant. At this time, CD147 was not detectable by flow cytometry (Figure 3c ). At day 100 post peripheral blood stem cell transplant, MM patient 2 was reported to be responding well to treatment, however, CD147 expression could now be detected by flow cytometry (Figure 3d ). One year post peripheral blood stem cell transplant, the patient was determined to be relapsing with circulating PCs, 50% PCs in the BM and high IgA/kappa levels (1170 and 5.4 mg/dl, respectively). CD147 expression had significantly increased at this time (Figure 3e ). Finally, initial assessment of MM patient 3 revealed the presence of CD147 (Figure 3f ). At this time, the patient was asymptomatic, yet concerns of an increasing malignant BM PC population (18%) and elevated kappa light chain (334 mg/dl) prompted the initiation of therapy. As therapy continued, the patient was determined to be responding well, with declining percentages of MM PCs and kappa light chain levels, however, the physician report stated a concern for possible progression. During this time, CD138 þ MM PCstaining revealed that CD147 levels had increased to a DMFI of 5.5 ( Figure 3g ) and a DMFI of 23.8 (Figure 3h ), respectively.
CypB stimulates myeloma cell DNA synthesis We next analyzed the ability of CypB, a natural CD147 ligand, to induce MM cell proliferation. Interestingly, in both IL-6-dependent HMCLs (Figure 4a) , addition of exogenous CypB also reproducibly increased DNA synthesis in both HMCLs, albeit to a lesser degree than IL-6. To ensure Cyp stimulation required CD147, we determined whether a blocking monoclonal antibody to CD147 would inhibit Cyp-stimulated DNA synthesis. The data shown in Table 1 provide additional evidence that CypB stimulates HMCL DNA synthesis. Although the addition of an isotype-matched control monoclonal antibody (MOPC-21) did not inhibit CypBstimulated responsiveness, the addition of the CD147-blocking antibody almost completely abolished the CypB-stimulated response. Moreover, the anti-CD147 antibody also slightly inhibited the magnitude of IL-6-stimulated DNA synthesis, suggesting a more general role for CD147 in MM cell proliferation. Lastly, cytokine-independent background proliferation observed in all the three HMCLs was also significantly inhibited by the addition of the blocking antibody. In experiments not shown, we determined that the anti-CD147 induced inhibition of MM cell proliferation was not secondary to induction of apoptosis. These results support the conclusion that CypB stimulation of MM cell DNA synthesis requires CD147 expression. Taken together, these data identify extracellular Cyps as novel molecules that may contribute to the overall proliferation levels of MM cells.
CD147 is necessary for CypB-mediated signaling in primary MM cells We next investigated whether CD147-expressing primary MM patient PCs also respond to CypB stimulation. Figure 4b demonstrates that, along with IL-6, CypB can stimulate DNA synthesis of CD147-expressing patient MM cells. Furthermore, DNA synthesis resulting from both IL-6 and CypB stimulation was significantly reduced by the addition of a CD147-blocking antibody. Figure 4c also shows that CypB stimulation results in MAPK phosphorylation. IL-6 was used as a positive control, whereas total MAPK levels served as a loading control. These results clearly demonstrate that CypB can not only specifically stimulate DNA synthesis through CD147 in HMCLs but can also stimulate primary patient MM cell DNA synthesis and MAPK phosphorylation.
CD147 expression is associated with cycling cells Next, we wished to more directly assess whether there is an association between MM cell CD147 expression and cell-cycle transit. To do this, we performed cell-cycle analysis on patient samples known to bimodally express CD147. After culturing cells overnight in the presence of BrdU, CD138 þ /CD147 bright and CD138 þ /CD147 dim cells were analyzed. Remarkably, the CD138 þ / CD147 bright cells were greatly enriched for cells within the S and G2/M phases of the cell cycle (20.6% and 5.2%, respectively), whereas the CD138 þ /CD147 dim cells resided almost exclusively within the G0/G1 phase (97.6%) (Figure 5a ; upper panel). Absolute levels of CD147 may also have an impact on the proliferative potential of MM cells. To address this possibility, we analyzed primary patient PCs that expressed CD147 in an unimodal manner, albeit over a wide, several-logs range. Of interest, the CD147 bright PCs were greatly enriched within the S (42%) and G2/M (50.3%) phases, whereas CD147 dim PCs resided almost exclusively within the G0/G1 phase (96.2%) (Figure 5a ; lower panel). Given that some investigators have proposed a correlation between CD45 þ PCs and the proliferative compartment of the MM clone, 34 CD147 bright / dim populations were also analyzed for CD45 expression. However, CD45 expression was comparable in both the CD147 bright and CD147 dim populations (data not shown). We also sorted CD138 þ PCs from MM patient 2 into CD147 dim and CD147 bright populations and cultured these cells for 5 days before assessing DNA synthesis. Figure 5b clearly shows that the CD147 bright PCs display high background proliferation and respond significantly to the addition of IL-6 and CypB. In comparison, proliferation levels displayed by the CD147 dim PCs, including basal DNA synthesis, were significantly lower. Wright-Giemsa staining demonstrated that CD147 dim PCs were morphologically smaller in size than CD147 bright PCs (data not shown). This finding was corroborated by flow cytometry, which demonstrated the lower level of forward scatter displayed by the CD147 dim PCs vs the CD147 bright PCs prior to sorting (Figure 5c ).
Given the striking differences in proliferation rates of CD147 bright and CD147 dim PCs, it remained possible that the CD147 dim PCs were not clonally related and might represent residual NBMPCs. To test this possibility, RNA was isolated from the CD147 bright and CD147 dim PC populations from MM patient 2 and subjected to IGHV analysis. However, Supplemental Figure 1 demonstrates that the IGHV-region genes in both CD147 bright and CD147 dim populations were identical to one another, as well as to the original unsorted primary patient cells. We also assessed CD147 mRNA expression levels in each subpopulation by reverse transcriptase PCR and verified diminished CD147 mRNA levels in the CD147 dim PCs (Supplemental Figure 2) . In results not shown, we also analyzed both subpopulations using fluorescence in situ hybridization, and both PC populations contained trisomies for 3, 7, 9 and 15 along with a monosomy 13.
siRNA-induced downregulation of CD147 decreases the proliferation of HMCLs Finally, we employed siRNA-knockdown strategies to definitively test the role of CD147 expression and MM cell proliferation. First, ALMC-2, ANBL-6 and KAS-6/1 cells were transfected with CD147-specific siRNA. Reduced CD147-expression levels were verified by flow cytometry (Figure 6a ; ALMC-2 shown as a representative HMCL in all Figure 6 panels). Moreover, IL-6-induced DNA synthesis (Figure 6b ) and cell proliferation (Figure 6c ) was significantly compromised following CD147 downregulation (P ¼ 0.0001 and P ¼ 0.0006 on day 3, respectively). We next determined whether CD147 downregulation had an effect on the number of apoptotic cells present in our HMCLs. In data not shown, the number of apoptotic cells did not increase following downregulation of CD147. Notably, cell-cycle analysis revealed that CD147 downregulation resulted in a significant increase in the number of cells in the G0/G1 phase of the cell cycle and a decrease in the number of cells in the G2/M phase of the cell cycle, as compared with cells transfected with control siRNA (Figure 6d ). Although the IL-6-induced proliferative capacity of HMCLs was decreased following downregulation of CD147, IL-6-mediated phosphorylation of MAPK remained robust (Figure 6e) , suggesting that the IL-6 signaling pathway overall was not compromised in these cells. In order to determine whether our results following downregulation of CD147 are specific to IL-6-induced signaling in MM cells or reflect an overall decrease in proliferative capacity, we next examined the effect of CD147 downregulation on CypB-induced proliferation. As shown in Figure 6f , CypB-induced DNA synthesis was significantly compromised following CD147 downregulation (P ¼ 0.033 on day 3). To further test whether the function of CD147 is independent of IL-6 signaling, we assessed CD147 expression in the IL-6-independent cell line RPMI 8226. This analysis revealed that these cells express very high levels of CD147 (DMFI ¼ 302, data not shown). Although CD147 siRNA only achieved a moderate reduction in the expression of CD147 (DMFI ¼ 85), DNA synthesis (Figure 6g ) was significantly compromised in these cells (P ¼ 0.001 day 3, Figure 6g ). Taken together, these data suggest that downregulation of CD147 decreases the overall proliferative capacity of MM cell lines, independent of the IL-6 signaling pathway. 
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DISCUSSION
Previous studies have demonstrated that the CD147 molecule is overexpressed in many carcinomas when compared with their normal and benign counterparts, 10, 11, 35, 36 and contributes to biological activities, which foster tumor progression. 13, 15, 37 However, prior to our studies, CD147 expression in MM cells and its potential biological function were unknown. Herein, we provide the first evidence that CD147-expression levels may become dysregulated in MM and, more importantly, that CD147 has a biological role in this disease.
Regarding CD147-expression levels, our data support the conclusion that CD147 mRNA levels are increased in MM PCs relative to MGUS PCs and NBMPCs. Analysis of publicly available gene-expression profiling data 38 similarly revealed that CD147 mRNA levels were elevated on MM PCs (n ¼ 559) vs MGUS PCs (n ¼ 44) (Po0.0001), while analysis of Mayo gene-expression profiling data (kindly provided by Dr Rafael Fonseca) also showed that MM PCs (n ¼ 53, previously untreated MM patients) expressed higher levels of CD147 mRNA than MGUS PCs (n ¼ 24) (Po0.0034). CD147 protein levels, as seen by DMFI, were elevated on MM cells vs MGUS cells (P ¼ 0.0020). We also analyzed CD147 expression in normal B cells, and although CD147 mRNA levels were low, CD147 was undetectable by western blot analysis. Moreover, intentional activation of normal B cells with polyclonal activation failed to upregulate CD147 expression (data not shown), suggesting that increased CD147 on MM cells may reflect genetic changes occurring during malignant transformation. Our discovery that many primary patient MM cells express elevated levels of CD147 prompted further investigation into the biological role of this molecule in malignant PCs. Here, we took advantage of our discovery of patients whose MM cells expressed CD147 in a bimodal manner as it provided us with a tool to isolate CD147 dim and CD147 bright MM PCs from the same patient and ask whether CD147 has a role in accelerated PC proliferation. In this regard, we clearly demonstrated that CD147 bright PCs were greatly enriched for cells within the S and G2/M phases of the cell cycle, whereas CD147 dim PCs largely resided within G0/G1 phase. Taken together with our data demonstrating that CD147 knockdown decreases MM cell proliferation, these results support a critical role for CD147 in MM cell proliferation. These findings are clinically significant because the proliferative rate of PCs, measured by the PC labeling index, is an important prognostic factor. Generally, MGUS PCs display an extremely low PC labeling index and PC numbers in these patients can remain stable for years. Elevations in PC labeling index are generally indicative of disease progression, whether it is from MGUS to MM or in progressing MM patients. 38, 39 Our observations that CD147-expression levels may increase with disease progression suggest a mechanism that may underlie elevations in PC labeling index.
Of note, CD45 expression has been suggested to identify the proliferative compartment within MM. 34 However, this conclusion remains controversial. For example, some have argued that the absence of this marker is associated with poor prognosis, 40, 41 whereas still others have contradicted this observation by stating that CD45 expression correlates with aggressiveness of the disease. 42 Finally, additional investigators have found no correlation or prognostic significance of CD45 within this disease. 43 Despite the controversy, to address the possibility that CD147 is a surrogate for CD45 expression, we also assessed CD45 expression on CD147 bright and CD147 dim PCs that had been pulsed with BrdU. However, we observed that CD45 þ PCs were found to reside in both CD147 bright and CD147 dim PC populations of the clone, thereby suggesting that CD147 expression marks a distinctive cellular state (data not shown).
Given the demonstrated role of CD147 in MM cell proliferation, we also carried out studies to determine if its natural ligand, extracellular Cyps, 19 could stimulate MM cell proliferation. Of interest, the CD147-Cyp interaction has been implicated as having an important role in inflammatory diseases by inducing MMP production. 9, 44, 45 Recent evidence also shows that the addition of extracellular Cyps to CD147-expressing tumor cells enhances both tumor-cell invasion and cellular proliferation. 46 Here, we show that CypB indeed stimulates DNA synthesis of MM CD147 bright but not CD147 dim PCs demonstrating the specificity of the interaction. Moreover, addition of a blocking antibody to CD147 abrogated Cyp-stimulated MM cell responses. The Cyp responsiveness of MM cells is consistent with recent work by Bauer et al. 23 , demonstrating that CypA and CypB support myeloma cell survival through STAT3 signaling. It is important to note that the HMCLs differed in their level of responsiveness to CypB. Although this observation needs further study, we speculate that this may result from variable levels of CypB autocrine signaling, that is, some HMCLs may secrete higher levels of CypB that would render the activity of exogenous CypB less obvious. Preliminary studies have demonstrated that not only is CypB found in the plasma of BM MM patient samples but it is also secreted by both HMCLs and CD138 þ primary patient samples (Arendt et al., unpublished observations). Collectively, our results, taken together with reports in the literature that blocking CD147 induces cell death in cancer cells 47 and silencing CD147 inhibits tumor progression, proliferation and migration activity, [48] [49] [50] suggest that CD147 may be an attractive molecule to target therapeutically in MM patients.
In addition to a role in MM cell proliferation, the CD147 molecule has a number of other activities with possible relevance to MM. For example, a characteristic feature of MM is that the tumor cell shares a reciprocal interaction with the BM microenvironment. The signals that are exchanged, causing immune suppression, angiogenesis and lytic bone lesions, have a critical role in maintaining tumor-cell growth and survival. Many of these distinguishing features have been attributed to CD147 in other cancers and an attractive hypothesis currently under study is that this molecule also exerts these additional activities within the MM cell niche. There are two relevant examples. First, CD147 overexpression has been shown to promote increased angiogenesis 16 and an angiogenic phenomenon is also observed as MGUS evolves into MM. 51, 52 Second, it has been shown that CD147 stimulates production of MMPs not only by surrounding stromal cells but also by tumor cells themselves. 15 Importantly, the dysregulated presence of MMPs in the MM microenvironment has been implicated in extracellular matrix remodeling and osteolytic bone destruction. 53 Other investigators have suggested that the higher glycosylated form of CD147 is the active form, inducing both MMP production 17, 30, 31 and metastasis 32, 33 Therefore, our observations that the CD147 glycosylation patterns of primary MM cells were quite varied support the need for an additional investigation into CD147 glycosylation status and bone disease in MM patients.
Finally, in a small cohort of patients from whom we had serial samples collected at various stages of disease, we obtained preliminary evidence that CD147-expression levels may correlate with disease progression (Figure 3 ). Taken together, these studies provide the rationale for future studies aimed at determining whether CD147 would function as a clinically useful biomarker of disease progression. We emphasize that larger studies utilizing serial samples are needed to formally test this possibility. Intriguingly, we observed some MGUS patients with higher CD147 levels and some MM patients with very low CD147 levels. Follow-up studies of both groups of patients over time are necessary to understand the significance of these observations. However, an anecdotal review of the small subset of MM patients with CD147 dim PCs indicated that these patients were undergoing preconditioning for ASCT (autologous stem cell transplant) or were asymptomatic and/or lacked CT/PET positivity at the time of sample draw. Lastly, the patterns of CD147 expression observed in patient samples are intriguing and varied from patient PCs with uniform CD147-negative, CD147 dim or CD147 bright expression to patient PCs that included only a small CD147 bright subpopulation. Longitudinal studies are also needed to determine whether the emergence of a CD147 bright PC population indeed correlates with progression across the disease continuum.
In summary, our studies demonstrate that CD147 is differentially expressed across the disease continuum both at the mRNA and protein levels, and signaling via this molecule may be necessary for MM PCs to transit the cell cycle. As CD147 has been implicated as having a significant role in other cancers, these results emphasize not only the possible importance of CD147 in the evolution of MGUS to MM tumor progression but also its potential role in tumor proliferation. Our studies provide an important novel foundation for future studies investigating the ability of CD147 to serve as an important biomarker of disease progression in the monoclonal gammopathies.
